Tim McCarthy FCCA, MBANon-Executive Chairman
Mr McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is also Chairman of Incanthera plc and 4basebio UK Societas. Mr McCarthy is also the former Chief Executive Officer and Finance Director of a number UK listed public and private companies, including Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, Mr McCarthy has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.
Dr Robert Zimmer MD, PhDPresident & Chief Science Officer
Dr. Robert Zimmer was the founder and chief executive officer of both ImmuPharma Switzerland and ImmuPharma France. He is an expert in clinical pharmacology and life cycle management. He was instrumental in developing a substantial number of products for clients including Roche, GlaxoSmithKline, Abbott, Searle, Sanofi-Aventis and Lilly. He began his career in Roche’s headquarters in Basle as coordinator of clinical pharmacology and international clinical leader. He subsequently joined Jago Pharma, the drug delivery company, and became a director and head of research and development at SkyePharma after it acquired JAGO. He obtained his MD at Strasbourg Medical School and his PHD at the University of Aix-Marseille.
Dimitri F Dimitriou MScChief Executive Officer & Co-Founder
Mr Dimitriou has 30 years’ experience in the pharmaceutical and biotech industry. He is a co-founder and CEO of ImmuPharma PLC, a pharmaceutical company listed on AIM of the London Stock Exchange since 2006. His past roles include Senior Director, Worldwide Business Development at GlaxoSmithKline, where his responsibilities included worldwide corporate deals with pharmaceutical and biotech companies. He held a similar role in Europe for Bristol-Myers Squibb. Prior to that, he spent 8 years at Procter & Gamble in senior marketing, R&D and business development positions and began his career in marketing at Novartis in 1987. He has 2 degrees from the University of London - a Bachelor’s in biochemistry from Kings College and a Master’s in pathology and toxicology from Imperial College Medical School.
Dr Tim Franklin PhD, MBAChief Operating Officer
Dr Franklin has 30 years’ experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.</p> <p>
Dr Franco Di MuzioSenior Non-Executive Director
Dr. Di Muzio has 40 years experience in the pharmaceutical and other industries, encompassing international management experience in business development, strategic marketing, international finance, M & A and re-engineering businesses. After graduating in Economics and Business in 1963, Dr Di Muzio worked for Colgate Palmolive and Nestle before joining Squibb (now Bristol Myers Squibb) for eight years. Dr Di Muzio became Executive Vice President of BMS' medical equipment and products division, Weck International Inc., in charge of Europe, Asia, Middle East and Africa. In 1990, he joined Glaxo Wellcome plc. (now GlaxoSmithKline plc) in London as Area Managing Director and Head of all GW's business in the Middle East, Africa and Turkey. Following early retirement from Glaxo Wellcome, in the beginning of 1998, he joined Alza International, the then world leader in drug delivery systems, as Managing Director, based in London, in charge of the company's business expansion in all markets outside the US and remained there until the end of 2000.
Dr Stéphane MéryNon-Executive Director
Dr Stéphane Méry has extensive experience in the Healthcare industry. He is currently CEO of Contronics Ltd, which designs and sells laboratory monitoring equipments, and until recently he was Partner at Beringea LLP, a $400m US/UK venture capital fund, where he was responsible for healthcare investments in Europe. Previously, he was the Fund Manager/CEO of the Bloomsbury Bioseed Fund, a Biotech and Medtech investment fund, which was behind the birth of successful companies such as Spirogen (sold to MedImmune), Abzema (listed on AIM), and Canbex, (recently sold to Ipsen). Prior to this, Stéphane was Associate Director, Worldwide Business Development, for SmithKline Beecham (GSK) where he was responsible for the negotiation of several major in-license deals and acquisitions. Before GSK, he was involved in the start-up of Double Helix Development, a successful strategic consultancy company specialising in R&D for the biotech and healthcare industry and recently sold to McCann. Just before, he worked as a management consultant at the American consultancy firm, ZS Associates, specialising on sales and marketing within the pharmaceutical industry. Stéphane is a Doctor in Veterinary Medicine, a trained Veterinary Pathologist, specialising in Nasal Toxicology at the Chemical Industry Institute of Toxicology (CIIT) in North Carolina, and holds an MBA from INSEAD (Fontainebleau).
Ewa Flynn ACCA, MAFinancial Controller & Company Secretary
After starting her career in Sumitomo Chemical plc, Ewa held several lead financial positions in various content publishers and online retailers, notably within the Amazon Group. Ewa has been an ACCA qualified Chartered Accountant since 2015 and holds a B.A. and M.A. in International Relations from Jagiellonian University in Cracow.<br />
Lisa BaderoonHead of Investor Relations
Lisa has spent over 25 years working within the City of London being involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their financial and corporate strategies aligned to stakeholder and investor interests, as well as a strong acumen in media communication. During this time, she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPOs), secondary high profile capital raisings and mergers and acquisitions both in the UK and internationally.</p> <p>Lisa had a successful career spanning 20 years as a Partner at Buchanan Communications, one of the leading City financial public relations agencies. As one of the youngest Board members, she was involved in the successful five-year earnout, as part of Buchanan being acquired by the FTSE 100 rated WPP Plc in 1997.</p> <p>Lisa founded Just B Communications Ltd in 2012 with the key objective of working with a more select number of clients and providing a greater degree of bespoke advisory services thus becoming more integral to the day to day corporate and strategic development for these businesses. She has successfully advised a number of public and private companies, at Board level, on corporate strategy, stakeholder and investor communications, capital raisings, dual listings, licensing and M&A. Media profiling, where required, has also played an important role in advisory activities.</p> <p>Lisa was appointed Head of Investor Relations at ImmuPharma in 2012.
Professor Sylviane Muller PhDResearch Director at CNRS & Co-founder of ImmuPharma France
Professor Muller earned her doctorate in sciences at the University of Strasbourg and focused on immune responses as a postdoctoral researcher at the Max Planck Institute for Immunobiology in Freiburg. Today, Prof. Muller is a research director at CNRS and supervises over 50 researchers at the CNRS Laboratory of Therapeutic Immunology and Chemistry at the Institute of Molecular and Cellular Biology in Strasbourg, which she has headed since 2001. She is also Head and Coordinator of the Drug Discovery Center for Cancer and Inflammation. Her expertise in peptide immunochemistry, combined with insights into the molecular and cellular pathways behind autoimmune disease, led to the discovery of Lupuzor.</p> <p>Professor Muller has filed for 24 patents and published more than 330 papers and reviews.</p> <p>For her contributions to the treatment and understanding of immune-inflammatory diseases, Professor Muller has received numerous awards, including the Apollo-B award from Roche (2007), the CNRS Silver Medal (2010), the CNRS Innovation Medal (2015) and the French Académie des Sciences Grand Prix Léon Velluz (2016).</p> <p>Professor Muller was also a founder of Neosystem, now Polypeptide-France, a leading peptide development and manufacturing company. She is the key inventor of ImmuPharma’s lead drug candidate Lupuzor™, for Lupus, and has been working in this field for more than ten years.<br />
Dr Gilles Guichard PhDResearch Director at CNRS, Université de Bordeaux & Co-founder of ImmuPharma France
Dr Guichard is senior researcher at the Centre National de la Recherche Scientifique (CNRS), France’s leading scientific research institution and is co-inventor of the heterocyclic ureas and oligoureas chemistry. He leads various research groups in the field of chemistry and peptide mimicry including one dedicated to the development and process improvement of the heterocyclic urea library. He received the CNRS bronze award for the excellence of his research activities and has made eight patented discoveries.
Dr Jean-Paul Briand PhDResearch Director at CNRS & Co-founder of ImmuPharma France
Dr Briand is CNRS Research Director at the ‘Immunologie et chimie thérapeutiques’ unit of the Centre National de la Recherche Scientifique, the largest scientific research institution in France. He is co-inventor of Lupuzor and Nucant molecules (ImmuPharma’s anticancer programme). He has extensive industry experience in peptide chemistry and synthesis in Peninsula, USA and was also a founder of Neosystem, now Polypeptide-France, a leading peptide development and manufacturing company.
Dr José Courty PhDResearch Director at CNRS
Dr Jose Courty, PhD Dr Courty is CNRS Research Director and head of the ‘Croissance, Réparation et Régénération Tissulaires’, a unit of both the Centre National de la Recherche Scientifique and the University Paris EST Créteil. He has been working for several years on tumour growth and angiogenesis and has good expertise in the field of growth factors and the regulation of their biological activities. He is a co-inventor of ImmuPharma’s lead compound for the treatment of cancer IPP-204106 molecule also named Nucant.
ImmuPharma’s researchers are based at the Centre National de la Recherche Scientifique in Strasbourg, Bordeaux and Paris.
Scientific Advisory Board
Dr. Daniel J. Wallace M.D., F.A.C.P., F.A.C.R (USA)Associate Director, Rheumatology Fellowship Program, Cedars-Sinai Medical Center, Los Angeles, Clinical Professor of Medicine, David Geffen School of Medicine at UCLA and Expert Reviewer, Medical Board of California.
Associate Director, Rheumatology Fellowship Program, Cedars-Sinai Medical Center, Los Angeles, Clinical Professor of Medicine, David Geffen School of Medicine at UCLA and Expert Reviewer, Medical Board of California.<br /> Dr Wallace is currently a Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA. His clinical practice is based at Cedars-Sinai, where he is involved in the care of 2,000 lupus patients, the largest practice of its kind in the United States and co- directs the Cedars Sinai Rheumatology fellowship program. The Wallace Rheumatic Disease Research Center currently runs over 30 clinical trials for patients with rheumatoid arthritis, lupus, ankylosing spondylitis, psoriatic arthritis and fibromyalgia. The center has been the recipient of multiple National Institute of Health grants. 20% of his time is spent in teaching and research, providing free medical care.</p> <p>Dr. Wallace is the recipient of the Lupus Foundation of America Humanitarian Award, Achievement award of the Lupus Research Institute, Spirit Award of the Scleroderma Foundation and the Jane Wyman Humanitarian Award of the Arthritis Foundation. His efforts have raised over $20 million for various rheumatic disease organizations.
Prof. David Isenberg MD, FRCP, FAMS (U.K.)Professor of Rheumatology, University College Hospital, London
Prof. Isenberg’s principal clinical interests have been in the development of disease activity and damage assessment tools in patients with lupus. Chair of the British Isles Assessment Group and also the Chair (1998-2003) of the Systemic Lupus International Collaborating Clinics group (SLICC). Has undertaken many roles for the arc in the past 20 years and is the past president of the British Society for Rheumatology (2004-2006) and is currently chairing the Society’s Biologics Register Committee. He is the 2010 recipient of the Evelyn Hess Prize from the Lupus Foundation of America for his contribution to lupus research and treatment.
Prof. Vibeke Strand MD, FACP, FACR (USA)Clinical Professor, Adjunct, Division of Immunology and Rheumatology, Stanford University School of Medicine
Vibeke Strand, MD, is an adjunct clinical professor in the Division of Immunology and Rheumatology at Stanford University School of Medicine. She has been a clinical rheumatologist for 32 years, previously in subspecialty practice in San Francisco and as a clinical research investigator, and senior director of clinical research at 3 pharmaceutical and biotech companies.
Prof. Cees GM Kallenberg M.D., Ph.D. (Netherlands)Professor, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen
Professor Cees GM Kallenberg received his medical training at the Medical School of the University of Leiden, The Netherlands. After getting his degree as an MD in 1972, he got additional training in surgery and served as a military MD in the Dutch Army. In 1975 he started his training as a resident in Internal Medicine at the Groningen University Hospital and was registered as internist in 1980. He worked as an internist and finished his PhD studies on the subject 'Raynaud's phenomenon and Systemic Autoimmune Disease' successfully in 1982. He further trained in immunology and medical immunology and was registered as immunologist and medical immunologist. He was appointed as associate professor in Internal Medicine – Clinical Immunology in 1985 and as a full professor in 1993.
Dr. Lee S. Simon MD, FACP, FACR (USA)Principal, SDG LLC and former FDA Division Director
Dr Simon has been a clinical Rheumatologist for 25 years. He is a fellow of the American College of Physicians (1991) and the American College of Rheumatology (1986). Dr. Simon has had extensive experience in drug development in the US, and has served on consulting advisory boards for many different companies.